Skip to main content


Table 1 Characteristics of clinical isolates used in this study

From: Biofilm formation by clinical isolates and the implications in chronic infections

Bacterial species Clinical isolates # of patients Pulsed- Field Type (PFTs) *Phenotype Site of isolation
E. coli 39 32 1 (n=4) ESBL+ (n=31) Wound culture (n=10)
    2 (n=5)   Blood (n=4)
    3 (n=3)   Urine (n=21)
    4 (n=7)   
    7 (n=5)   
    Other (n=15)   
K. pneumoniae 54 33 1 (n=6) MDR (n=54) Wound culture (n=39)
    2 (n=8)   Blood (n=10)
    3,4,14,16,17, 18 (n=5)   Respiratory (n=5)
    Other (n=10)   
P. aeruginosa 36 17 1 (n=7) MDR (n=28) Wound culture (n=29)
    2, 18 (n=5)   Blood (n=7)
    Other (n=19)   
A. baumannii 53 47 1 (n=13) MDR (n=46) Wound culture (n=31)
    5 (n=4)   Blood (n=20)
2,3,4, 6,7,14 (n=5)   Urine (n=1)
    Other (n=6)   Respiratory (n=1)
S. aureus 23 21 USA100 (n=10) MRSA (n=15) Wound culture (n=14)
    USA200, USA800 (n=4) MSSA (n=8) Blood (n=4)
    USA300 (n=2)   Respiratory (n=5)
    USA700 (n=3)   
  1. *A multidrug-resistant (MDR) organism was defined as any extended spectrum beta-lactamase (ESBL)-producing bacteria, or if resistant to all tested antimicrobials in 3 or more classes of antimicrobial agents (penicillins/cephalosporins, carbapenems, aminoglycosides, and quinolones) not including tetracyclines or colistin.